ZEO ScientifiX (OTCQB: ZEOX) to lead A4M longevity Masterclass

Q: How big is the longevity therapy market mentioned by ZEO ScientifiX?

ZEO references the overall longevity therapy market as $29.9 billion , citing The Business Research Company’s 2026 figure. This contextualizes the scale of commercial opportunity surrounding regenerative and longevity therapies targeted by its educational and clinical initiatives.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

ZEO ScientifiX, Inc. filed an 8-K to highlight a new educational partnership with the American Academy of Anti-Aging Medicine (A4M) for Longevity SpringFest 2026. ZEO will serve as A4M’s official regenerative medicine education partner and lead a full-day Masterclass on April 9, 2026, in West Palm Beach, Florida.

The collaboration provides ZEO direct access to A4M’s network of 26,000 physicians and health care practitioners across more than 120 countries, positioning the company within the broader $29.9 billion longevity therapy market. ZEO describes itself as a clinical-stage biopharmaceutical company focused on regenerative biologics, operating from Nova Southeastern University’s $100 Million Center of Collaborative Research.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Masterclass date: April 9, 2026 Longevity therapy market size: $29.9 billion A4M network practitioners: 26,000 physicians and health care practitioners +2 more

5 metrics

Masterclass date April 9, 2026 Regenerative & Longevity Medicine Masterclass in West Palm Beach

Longevity therapy market size $29.9 billion Overall longevity therapy market (The Business Research Company, 2026)

A4M network practitioners 26,000 physicians and health care practitioners Size of A4M’s global educational network

Countries represented over 120 nations Geographic reach of A4M’s practitioner network

Research center scale $100 Million Center of Collaborative Research Facility at Nova Southeastern University where ZEO operates

Key Terms

regenerative medicine, longevity therapy market, clinical-stage biopharmaceutical company, regenerative biologics, +1 more

5 terms

regenerative medicine medical

"official educational partner for regenerative medicine with the American Academy"

A field of medical treatments that aims to repair, replace or regenerate damaged tissues and organs using approaches such as cell or gene therapies, engineered tissues, and biologically active materials. It matters to investors because successful regenerative therapies can create entirely new, high-value markets and replace chronic treatments, offering large potential returns but also long development timelines, heavy regulation and high technical risk—like betting on a promising new technology that could either revolutionize care or fail in trials.

longevity therapy market financial

"emphasizing the Company’s position in the overall $29.9 billion longevity therapy market"

clinical-stage biopharmaceutical company financial

"ZEO ScientifiX, Inc. (OTCQB: ZEOX) is an SEC-reporting, clinical-stage biopharmaceutical company"

A clinical-stage biopharmaceutical company develops drugs or medical therapies that are being tested in people in formal clinical trials but do not yet have any approved, marketed products. For investors, these firms behave like prototype makers: their value depends heavily on trial results and regulatory decisions, so they can swing widely on a single study, consume cash while testing, and offer either large upside if trials succeed or big downside if they fail.

regenerative biologics medical

"focused on the research, development, and manufacturing of regenerative biologics"

forward-looking statements regulatory

"Certain statements contained in this press release should be considered forward-looking statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Understanding 8-K Material Events →

03/31/2026 - 08:15 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 31, 2026

ZEO SCIENTIFIX, INC.

(Exact name of registrant as specified in its charter)

Nevada		000-55008		47-4180540
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3321 College Avenue, Suite 246 Davie, Florida		33314
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (888) 963-7881

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class		Trading Symbol		Name of each exchange on which registered
None		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the Company,” “ZEO,” “we,” “us” and “our” refer to Zeo ScientifiX, Inc.

Item 8.01 Other Events.

On March 31, 2026, ZEO issued a press release announcing its role as the official educational partner for regenerative medicine with the American Academy of Anti-Aging Medicine (A4M) at the Longevity SpringFest 2026, where ZEO will lead a specialized, full-day Masterclass on regenerative and longevity medicine. The Masterclass will be held on April 9, 2026 in West Palm Beach, Florida.

A copy of the press release is included as Exhibit 99.1 to this Report.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit No.		Description
99.1		Press Release, dated March 31, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 31, 2026	ZEO SCIENTIFIX, INC.

	By:	/s/ Ian T. Bothwell
		Ian T. Bothwell Chief Executive Officer and Chief Financial Officer

Exhibit 99.1

ZEO ScientifiX Solidifies Role as Official Regenerative Medicine Educational Partner for A4M at Longevity SpringFest 2026

ZEO Joins Publicly Traded Longevity Companies Like Niagen Bioscience (NASDAQ: NAGE) as Leaders in A4M’s Educational Global Practitioner Network

FORT LAUDERDALE, Fla. – March 31, 2026 – ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO” or the “Company”), a clinical-stage biotechnology company, today announced its role as the official educational partner for regenerative medicine with the American Academy of Anti-Aging Medicine (A4M) at the Longevity SpringFest 2026.

Modeled after A4M’s prestigious Professional Medical Education (PME) series, ZEO will serve as the "official arm of education" for regenerative medicine. The Company will lead a specialized, full-day Masterclass on April 9, 2026, in West Palm Beach, providing evidence-based training to attending physicians. This collaboration allows ZEO direct access to A4M’s network of 26,000 physicians and health care practitioners representing over 120 nations.

This strategic partnership places ZEO alongside other industry-leading public companies that are partners within the A4M educational-network, including NASDAQ-listed Niagen Bioscience (NAGE) and InBody (KRX: 041830), emphasizing the Company’s position in the overall $29.9 billion longevity therapy market (The Business Research Company, 2026).

“We are incredibly excited to bring this level of specialized physician education to West Palm Beach,” said Dr. George C. Shapiro MD, Chief Medical Officer of ZEO. “By modeling this Masterclass after A4M’s renowned Professional Medical Education series, ZEO is helping set a new standard for how regenerative medicine is taught and implemented. As Chair of the educational session, my goal is to ensure clinicians leave with a rigorous, evidence-based framework to safely and effectively lead the next wave of regenerative and longevity medicine.”

The Regenerative & Longevity Medicine Masterclass

Designed for advanced practitioners, the program will cover:

●

Scientific Foundations: Differentiating cellular vs. acellular biologics and manufacturing quality standards.

●

Clinical Integration: Real-world applications for musculoskeletal, orthopedic, and oncology-adjacent care.

●

Regulatory Compliance: Navigating federal and Florida-specific biologic legislation.

About ZEO ScientifiX, Inc. ZEO ScientifiX, Inc. (OTCQB: ZEOX) is an SEC-reporting, clinical-stage biopharmaceutical company focused on the research, development, and manufacturing of regenerative biologics. Operating out of Nova Southeastern University’s $100 Million Center of Collaborative Research, the Company translates emerging science into scalable clinical solutions. For more information, visit https://zeoscientifix.com.

Forward-Looking Statements Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Actual results could vary dramatically. ZEO has no intention and specifically disclaims any duty to update the information in this press release.

Media Contact:

ZEO ScientifiX, Inc.

Karlista Maroney

Director of Growth Strategy

IR@zeoscientifix.com

Source: View Original Filing on SEC EDGAR

FAQ

What did ZEOX disclose in its latest 8-K filing?

ZEO ScientifiX disclosed it has become the official regenerative medicine educational partner of A4M at Longevity SpringFest 2026, leading a full-day Masterclass for physicians and practitioners in West Palm Beach on April 9, 2026.

What is ZEO ScientifiX’s role with A4M at Longevity SpringFest 2026?

ZEO ScientifiX will act as A4M’s “official arm of education” for regenerative medicine, delivering a specialized, evidence-based Masterclass modeled on A4M’s Professional Medical Education series to advanced practitioners attending the Longevity SpringFest 2026 event.

How large is the practitioner network ZEO gains access to through A4M?

Through this collaboration, ZEO gains direct access to A4M’s network of 26,000 physicians and health care practitioners across more than 120 nations, giving it broad exposure within the global longevity and regenerative medicine community via A4M’s educational ecosystem.

How big is the longevity therapy market mentioned by ZEO ScientifiX?

ZEO references the overall longevity therapy market as $29.9 billion, citing The Business Research Company’s 2026 figure. This contextualizes the scale of commercial opportunity surrounding regenerative and longevity therapies targeted by its educational and clinical initiatives.

What kind of company is ZEO ScientifiX (ZEOX)?

ZEO ScientifiX is described as an SEC-reporting, clinical-stage biopharmaceutical company focused on researching, developing, and manufacturing regenerative biologics, operating from Nova Southeastern University’s $100 Million Center of Collaborative Research to translate emerging science into scalable clinical solutions.

When and where will ZEO ScientifiX’s Masterclass take place?

The Regenerative & Longevity Medicine Masterclass will take place on April 9, 2026, in West Palm Beach, Florida. It is designed for advanced practitioners and aims to provide rigorous, evidence-based training in regenerative and longevity medicine techniques and frameworks.

Filing Exhibits & Attachments

4 documents

Press Releases

EX-99.1 EXHIBIT 99.1 9.4 KB